Trending topics on coumarin and its derivatives in 2020

A Carneiro, MJ Matos, E Uriarte, L Santana - Molecules, 2021 - mdpi.com
Coumarins are naturally occurring molecules with a versatile range of activities. Their
structural and physicochemical characteristics make them a privileged scaffold in medicinal …

Mechanisms of resistance to second-generation antiandrogen therapy for prostate cancer: actual knowledge and perspectives

F Pinto, F Dibitetto, M Ragonese, P Bassi - Medical Sciences, 2022 - mdpi.com
Prostate cancer therapy for locally advanced and metastatic diseases includes androgen
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …

G-quadruplex DNA contributes to RNA polymerase II-mediated 3D chromatin architecture

J Yuan, X He, Y Wang - Nucleic Acids Research, 2023 - academic.oup.com
High-order chromatin organization plays an important role in biological processes and
disease development. Previous studies revealed a widespread occurrence of guanine …

Installation of pargyline, a LSD1 inhibitor, in the HDAC inhibitory template culminated in the identification of a tractable antiprostate cancer agent

R Ojha, IC Chen, CM Hsieh, K Nepali… - Journal of Medicinal …, 2021 - ACS Publications
Pragmatic insertion of pargyline, a LSD1 inhibitor, as a surface recognition part in the HDAC
inhibitory pharmacophore was planned in pursuit of furnishing potent antiprostate cancer …

Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment

S He, X Chu, Y Wu, J Jiang, P Fang… - Journal of Medicinal …, 2023 - ACS Publications
Aldo-keto reductase 1C3 (AKR1C3) is correlated with tumor development and
chemotherapy resistance. The catalytic activity of the enzyme has been recognized as one …

Aldo-Keto reductase 1C3 inhibitor prodrug improves pharmacokinetic profile and demonstrates in vivo efficacy in a prostate cancer xenograft model

K Maddeboina, SK Jonnalagadda… - Journal of Medicinal …, 2023 - ACS Publications
Aldo-keto reductase 1C3 (AKR1C3) is overexpressed in castration-resistant prostate cancer
where it acts to drive proliferation and aggressiveness by producing androgens. The …

[HTML][HTML] Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3

X Yu, J Yan, Y Li, J Cheng, L Zheng, T Fu… - Food & Nutrition …, 2023 - ncbi.nlm.nih.gov
Background Prostate cancer is the second leading cause of cancer-related death among
males in America. The patients' survival time is significantly reduced after prostate cancer …

Discovery of novel aldo-keto reductase 1C3 inhibitors as chemotherapeutic potentiators for cancer drug resistance

S He, Y Liu, X Chu, Q Li, W Lyu, Y Liu… - ACS medicinal …, 2022 - ACS Publications
As a crucial target which is overexpressed in a variety of cancers, aldo-keto reductase 1C3
(AKR1C3) confers chemotherapeutic resistance to many clinical agents. However, a limited …

Non-coding variants in cancer: mechanistic insights and clinical potential for personalized medicine

M Lange, R Begolli, A Giakountis - Non-coding RNA, 2021 - mdpi.com
The cancer genome is characterized by extensive variability, in the form of Single Nucleotide
Polymorphisms (SNPs) or structural variations such as Copy Number Alterations (CNAs) …

[HTML][HTML] Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer

AC Pippione, S Kovachka, C Vigato, L Bertarini… - European Journal of …, 2024 - Elsevier
AKR1C3 is an enzyme that is overexpressed in several types of radiotherapy-and
chemotherapy-resistant cancers. Despite AKR1C3 is a validated target for drug …